Viewing entries in
stories 4

Molly Downhour

Molly Downhour

The therapy I worked on that I am most proud of is Erivedge, an oral hedgehog inhibitor FDA approved for metastatic basal cell carcinoma. I was the research nurse for the Phase I clinical trial and dosed the first patient in the world on this drug (and for this novel targeted pathway).